The CXCL13 hub in obesity-related metabolic inflammation: regulation of spatiotemporal heterogeneity and targeted strategies
Journal of Endocrinology · 01.04.2026 · 269 (1)
DOI: 10.1530/joe-25-0295 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Endocrinology, online erschienen am 23.03.2026. Verfasst von Mengke Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, West China Second University Hospital, and Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Bi…. Hauptthemen laut MEDLINE: Chemokine CXCL13, Obesity, Inflammation. Die Arbeit nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
C-X-C motif chemokine ligand 13 (CXCL13) is a crucial regulator of lymphoid tissue development and immune function. It orchestrates homeostasis in secondary lymphoid organs, inflammatory responses in tertiary lymphoid structures (TLSs), and immunometabolic balance within fat-associated lymphoid clusters (FALCs) by mediating the homing of CXCR5+ cells and activating stromal cells. In the context of obesity-related metabolic inflammation, CXCL13 acts as a central hub of immunometabolic dysregulation, driving pathological processes across multiple organs with significant organ- and stage-specific heterogeneity, which reflects spatiotemporal heterogeneity. It mediates the pathological transformation of FALCs in adipose tissue, inducing insulin resistance; promotes TLS formation within pancreatic islets, accelerating β-cell destruction; dynamically regulates atherosclerotic plaque stability in the blood vessels; and undergoes a functional shift from compensatory suppression to profibrotic and procarcinogenic roles during the progression of liver disease. The effects of CXCL13 are highly dependent on the local microenvironment, exhibiting both pro-inflammatory and repair-suppressive effects in diabetic complications. Although targeted therapies show experimental promise, the context-dependent functions of CXCL13 – encompassing both physiological protection and pathological disruption – along with its organ and stage specificity, necessitate spatiotemporally precise interventions. This review systematically elucidates the pivotal role of CXCL13 in obesity-related metabolic inflammation, providing a theoretical foundation for the development of precision intervention strategies tailored to disease subtypes, stages, and specific organ targeting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, West China Second University Hospital, and Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Sichuan University, Chengdu, Chi…
- State Key Laboratory of Biotherapy and Cancer Center/National Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, China.
ORCID-Profile: Mengke Huang, Yongmei Jiang, Ting Liu
Zitieren
APA
Huang, M., Chen, X., Jiang, Y., & Liu, T. (2026). The CXCL13 hub in obesity-related metabolic inflammation: regulation of spatiotemporal heterogeneity and targeted strategies. Journal of Endocrinology, 269(1). https://doi.org/10.1530/joe-25-0295
Vancouver
Huang M, Chen X, Jiang Y, Liu T. The CXCL13 hub in obesity-related metabolic inflammation: regulation of spatiotemporal heterogeneity and targeted strategies. Journal of Endocrinology. 2026;269(1). doi:10.1530/joe-25-0295
BibTeX
@article{Huang2026,
author = {Huang, Mengke and Chen, Xiaolin and Jiang, Yongmei and Liu, Ting},
title = {The CXCL13 hub in obesity-related metabolic inflammation: regulation of spatiotemporal heterogeneity and targeted strategies},
journal = {Journal of Endocrinology},
year = {2026},
volume = {269},
number = {1},
doi = {10.1530/joe-25-0295}
}
EUVIMED